Publications by authors named "Bruno Anspach"
Article Synopsis
- Limited evidence exists about how much wheezing in young children is linked to respiratory syncytial virus (RSV) infections in their early years.
- A study tracked 2-year-olds in 8 countries until they turned six, assessing wheeze occurrences and calculating the population attributable risk (PAR) for those with previous RSV lower respiratory tract infections.
- Results showed that children with RSV-LRTI had significantly higher incidences of wheezing, suggesting that preventing RSV infections in early childhood could reduce wheezing episodes in later years.
Background: A single-dose investigational respiratory syncytial virus (RSV) vaccine, RSV prefusion protein F3 (RSVPreF3), was co-administered with a single-dose quadrivalent influenza vaccine (FLU-D-QIV) in a phase 3, randomized, controlled, multicenter study in healthy, non-pregnant women aged 18-49 years.
Methods: The study was observer-blind to evaluate the lot-to-lot consistency of RSVPreF3, and single-blind to evaluate the immune response, safety, and reactogenicity of RSVPreF3 co-administered with FLU-D-QIV.
Results: A total of 1415 participants were included in the per-protocol set.
Background: Respiratory syncytial virus (RSV) fusion protein stabilized in the prefusion conformation (RSVPreF3) was under investigation as a maternal vaccine.
Methods: This phase 2, randomized, placebo-controlled, single-dose, multicenter study enrolled healthy, nonpregnant women, randomized 1:1:1:1:1 to 5 parallel groups studying RSVPreF3 (60 or 120 µg) coadministered with diphtheria, tetanus, and acellular pertussis vaccine (dTpa) or placebo, and dTpa coadministered with placebo. Safety and humoral immune responses were assessed.